Syndax Pharmaceuticals Inc header image

Syndax Pharmaceuticals Inc

SNDX

Equity

ISIN null / Valor 24112479

NASDAQ (2026-10-06)
USD 17.37-2.58%

Syndax Pharmaceuticals Inc
UMushroom community rating:

star star star star star
4.28 18 votes No rating yet
NegativeNeutralPositive

About company

Syndax Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for cancer treatment. The company aims to extend and improve the lives of cancer patients by leveraging cutting-edge scientific research and advancements. Syndax collaborates with various stakeholders in the medical and scientific communities to identify and develop promising drug candidates. The company's pipeline includes treatments designed to address unmet medical needs in oncology, with a particular emphasis on novel mechanisms of action and overlooked aspects of cancer biology. Through these efforts, Syndax seeks to bring new, effective treatment options to market, enhancing patient outcomes and advancing the field of cancer therapy.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

5.91%1Y
36.1%3Y
-1.70%5Y

Performance

51.0%1Y
58.0%3Y
55.6%5Y

Volatility

Market cap

1551 M

Market cap (USD)

Daily traded volume (Shares)

1,135,156

Daily traded volume (Shares)

1 day high/low

12.75 / 12.4

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.28

18 votes
Performance:
starstarstarstarstar
3.94
Innovation:
starstarstarstarstar
4.33
Society:
starstarstarstarstar
4.44
Nature:
starstarstarstarstar
4.17
Liam Hawkeswood
Switzerland, 18 Nov 2025
star star star star star
Liam Hawkeswood
Switzerland, 11 Nov 2025
star star star star star
****** Panggabean
UK, 09 Nov 2025
star star star star star
High risk and volatile performance. However, it has high upside potential and people are anticipating future returns

EQUITIES OF THE SAME SECTOR

IQVIA Holdings Inc
IQVIA Holdings Inc IQVIA Holdings Inc Valor: 39103858
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.30%USD 259.98
Envista Holdings Corporation
Envista Holdings Corporation Envista Holdings Corporation Valor: 49153522
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.30%USD 23.27
Humana Inc
Humana Inc Humana Inc Valor: 940174
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.05%USD 404.27
Allogene Therapeutics Inc
Allogene Therapeutics Inc Allogene Therapeutics Inc Valor: 43756548
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.67%USD 1.46
Attendo AB
Attendo AB Attendo AB Valor: 30491576
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.34%SEK 125.60
International Flavors & Fragrances Inc
International Flavors & Fragrances Inc International Flavors & Fragrances Inc Valor: 941876
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.79%USD 83.92
Zimmer Biomet Holdings Inc
Zimmer Biomet Holdings Inc Zimmer Biomet Holdings Inc Valor: 1262932
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.06%USD 89.68
SHL Telemedicine Ltd
SHL Telemedicine Ltd SHL Telemedicine Ltd Valor: 1128957
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
4.00%CHF 1.04
Neumora Therapeutics Inc
Neumora Therapeutics Inc Neumora Therapeutics Inc Valor: 129329732
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-10.34%USD 0.47
Gyre Therapeutics Inc
Gyre Therapeutics Inc Gyre Therapeutics Inc Valor: 130270397
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.67%USD 7.08